Monoamine systems in the discriminative effects of spiradoline, a kappa-opioid agonist.
S G Holtzman, G F Steinfels
文献索引:Pharmacol. Biochem. Behav. 47(3) , 575-8, (1994)
全文:HTML全文
摘要
The results of studies on mice indicate that the antinociceptive effects of kappa-opioid agonists are due, in part, to activation of the 5-HT2 type of serotonin receptor. One objective of this study was to determine if the discriminative effects of spiradoline, a kappa-opioid agonist, are mediated by 5-HT2 receptors in rats also. A second objective was to confirm findings that dopamine receptor antagonists produce spiradoline-like discriminative effects (Ohno et al., 1992). Rats were trained to discriminate between spiradoline (3.0 mg/kg) and saline in a discrete-trial avoidance/escape procedure. In subsequent tests of stimulus generalization, the discriminative effects of spiradoline were not mimicked by fenfluramine (0.3-10 mg/kg) or fluoxetine (1.0-10 mg/kg), drugs that enhance serotonergically mediated neurotransmission, nor were they blocked by the 5-HT2 antagonists pirenperone (0.01-1.0 mg/kg) and ketanserin (0.1-10 mg/kg), or potentiated by fluoxetine pretreatment. Neither the dopamine receptor antagonists haloperidol (0.01-0.3 mg/kg) and sulpiride (3.0-100 mg/kg) nor the agonists apomorphine (0.03-0.3 mg/kg) and d-amphetamine (0.1-3.0 mg/kg) engendered spiradoline-like discriminative effects. These results demonstrate further the pharmacological specificity of the discriminative effects of spiradoline, but provide no evidence for mediation by serotonergic or dopaminergic systems.
相关化合物
相关文献:
2000-11-01
[Microvasc. Res. 60(3) , 261-8, (2000)]
1991-08-01
[Pharmacol. Biochem. Behav. 39(4) , 991-6, (1991)]
1999-03-01
[Pharmacol. Biochem. Behav. 62(3) , 543-7, (1999)]
1988-02-01
[Neuropharmacology 27(2) , 123-7, (1988)]
1987-01-01
[Gen. Pharmacol. 18(3) , 225-7, (1987)]